A Comprehensive Immune Checkpoint Phenotype Predicts Response and Survival to PD ‐1 Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Documenti analoghi

• Increased PD‐1/PD‐L1 Immune Checkpoint Expression Is Associated With Oral Squamous Cell Carcinoma in Never‐Smokers and Never‐Drinkers
  di: Mathias Fiedler, et al.
  Pubblicazione: (2024)
• Perioperative Piperacillin/Tazobactam Reduces Early Onset SSI in Preirradiated Patients Undergoing Microvascular Head and Neck Reconstruction
  di: Johannes G. Schuderer, et al.
  Pubblicazione: (2026)
• Response to Letter to the Editor: Fully COVID ‐19 Vaccinated Status Enhanced the Efficacy of Immune Checkpoint Inhibitors in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
  di: Chien‐Chung Wang, et al.
  Pubblicazione: (2026)
• Prognosis After Discontinued Treatment due to Immune‐Related Adverse Events in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma
  di: Hiromasa Ishihara, et al.
  Pubblicazione: (2025)
• Risk Factors for Progressive Disease After Immune Checkpoint Inhibitor Therapy in Head and Neck Squamous Cell Carcinoma
  di: Seo Yoon Jang, et al.
  Pubblicazione: (2025)